Literature DB >> 34825185

SF5- and SCF3-substituted tetrahydroquinoline compounds as potent bactericidal agents against multidrug-resistant persister Gram-positive bacteria.

Kenneth I Onyedibe1,2, Neetu Dayal1, Herman O Sintim1,2,3.   

Abstract

Bacteria persister cells are immune to most antibiotics and hence compounds that are active against persister bacteria are needed. We screened a chemical library of SF5- and SCF3-substituted tetrahydroquinoline compounds, synthesized via the Povarov reaction, for antibacterial activity and identified active compounds that displayed good activities against many Gram-positive bacteria, including persisters. The most potent of these compounds, HSD1835, inhibited the growth of drug-resistant Gram-positive bacterial pathogens (including clinical strains) at concentrations ranging from 1 μg mL-1 to 4 μg mL-1. Several of the SCF3- and SF5-containing compounds were active against methicillin-resistant Staphylococcus aureus (MRSA) and against the two most fatal strains of vancomycin-resistant Enterococcus (VRE), VRE faecalis and VRE faecium. The compounds showed bactericidal activity against stationary phase persister MRSA in time-kill assays. Mechanistic studies showed that HSD1835 acts by disrupting bacterial membranes. Scanning electron microscopy (SEM) was used to confirm bacterial membrane disruption. Interestingly, in a 30 day serial exposure experiment, MRSA remained susceptible to low-dose HSD1835 whilst resistance to ciprofloxacin and mupirocin emerged by day 10. Analogs of HSD1835, which did not bear the SF5 or SCF3 moieties, were inactive against bacteria. Recent reports (G. A. Naclerio, N. S. Abutaleb, K. I. Onyedibe, M. N. Seleem and H. O. Sintim, RSC Med. Chem. 2020, 11, 102-110 and G. A. Naclerio, N. S. Abutaleb, D. Li, M. N. Seleem and H. O. Sintim, J. Med. Chem. 2020, 63(20), 11934-11944) also demonstrated that adding the SF5 or SCF3 groups to a different scaffold (oxadiazoles) enhanced the antibacterial properties of the compounds, so it appears that these groups are privileged moieties that enhance the antimicrobial activities of compounds. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34825185      PMCID: PMC8597427          DOI: 10.1039/d1md00211b

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  36 in total

Review 1.  Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Authors:  Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler
Journal:  Nat Rev Microbiol       Date:  2019-04       Impact factor: 60.633

2.  Prevalence of decreased susceptibility to triclosan in Salmonella enterica isolates from animals and humans and association with multiple drug resistance.

Authors:  Justin L Copitch; Rebekah N Whitehead; Mark A Webber
Journal:  Int J Antimicrob Agents       Date:  2010-06-11       Impact factor: 5.283

3.  A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus.

Authors:  Wooseong Kim; Guijin Zou; Taylor P A Hari; Ingrid K Wilt; Wenpeng Zhu; Nicolas Galle; Hammad A Faizi; Gabriel L Hendricks; Katerina Tori; Wen Pan; Xiaowen Huang; Andrew D Steele; Erika E Csatary; Madeline M Dekarske; Jake L Rosen; Noelly de Queiroz Ribeiro; Kiho Lee; Jenna Port; Beth Burgwyn Fuchs; Petia M Vlahovska; William M Wuest; Huajian Gao; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-29       Impact factor: 11.205

4.  Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome.

Authors:  Riad Khatib; Leonard B Johnson; Mohamad G Fakih; Kathleen Riederer; Amir Khosrovaneh; M Shamse Tabriz; Mamta Sharma; Sajjad Saeed
Journal:  Scand J Infect Dis       Date:  2006

5.  Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study.

Authors:  Håkan Hanberger; Sten Walther; Marc Leone; Philip S Barie; Jordi Rello; Jeffrey Lipman; John C Marshall; Antonio Anzueto; Yasser Sakr; Peter Pickkers; Peter Felleiter; Milo Engoren; Jean-Louis Vincent
Journal:  Int J Antimicrob Agents       Date:  2011-07-28       Impact factor: 5.283

6.  Inhibitors of Intracellular Gram-Positive Bacterial Growth Synthesized via Povarov-Doebner Reactions.

Authors:  Neetu Dayal; Clement Opoku-Temeng; Haroon Mohammad; Nader S Abutaleb; Delmis Hernandez; Kenneth Ikenna Onyedibe; Modi Wang; Matthias Zeller; Mohamed N Seleem; Herman O Sintim
Journal:  ACS Infect Dis       Date:  2019-09-25       Impact factor: 5.084

7.  Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria.

Authors:  George A Naclerio; Nader S Abutaleb; Kenneth I Onyedibe; Mohamed N Seleem; Herman O Sintim
Journal:  RSC Med Chem       Date:  2019-12-16

8.  Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time.

Authors:  Riad Khatib; L B Johnson; M Sharma; M G Fakih; R Ganga; K Riederer
Journal:  Scand J Infect Dis       Date:  2009

9.  Inappropriate Use of Antibiotics and Its Associated Factors among Urban and Rural Communities of Bahir Dar City Administration, Northwest Ethiopia.

Authors:  Endalew Gebeyehu; Laychiluh Bantie; Muluken Azage
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

10.  Characterization of methicillin-susceptible and -resistant staphylococci in the clinical setting: a multicentre study in Nigeria.

Authors:  Adebayo Shittu; Omotayo Oyedara; Fadekemi Abegunrin; Kenneth Okon; Adeola Raji; Samuel Taiwo; Folasade Ogunsola; Kenneth Onyedibe; Gay Elisha
Journal:  BMC Infect Dis       Date:  2012-11-02       Impact factor: 3.090

View more
  1 in total

1.  Comparative Studies to Uncover Mechanisms of Action of N-(1,3,4-Oxadiazol-2-yl)benzamide Containing Antibacterial Agents.

Authors:  George A Naclerio; Kenneth I Onyedibe; Caroline W Karanja; Uma K Aryal; Herman O Sintim
Journal:  ACS Infect Dis       Date:  2022-03-17       Impact factor: 5.578

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.